These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19076287)

  • 1. Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients.
    Kocak H; Gumuslu S; Sahin E; Ceken K; Gocmen YA; Yakupoglu G; Ersoy FF; Tuncer M
    Nephrology (Carlton); 2009 Apr; 14(3):273-80. PubMed ID: 19076287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative stress and asymmetric dimethylarginine is independently associated with carotid intima media thickness in peritoneal dialysis patients.
    Kocak H; Gumuslu S; Ermis C; Mahsereci E; Sahin E; Gocmen AY; Ersoy F; Suleymanlar G; Yakupoglu G; Tuncer M
    Am J Nephrol; 2008; 28(1):91-6. PubMed ID: 17914250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients.
    Furuya R; Kumagai H; Odamaki M; Takahashi M; Miyaki A; Hishida A
    Nephron Clin Pract; 2009; 112(4):c255-61. PubMed ID: 19546585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Asymmetric Dimethylarginine and Pentosidine in Dialysis Effluent of Peritoneal Dialysis Patients -A possible intraperitoneal crosstalk between asymmetric dimethylarginine and advanced glycation end products in peritoneal dialysis patients.
    Ishida M; Kakuta T; Miyakogawa T; Tatsumi R; Matsumoto C; Fukagawa M
    Tokai J Exp Clin Med; 2016 Jun; 41(2):97-100. PubMed ID: 27345001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetric dimethylarginine in hemodialysis, hemodiafiltration, and peritoneal dialysis.
    Eiselt J; Rajdl D; Racek J; Siroká R; Trefil L; Opatrná S
    Artif Organs; 2010 May; 34(5):420-5. PubMed ID: 20633156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine.
    Yilmaz MI; Saglam M; Caglar K; Cakir E; Sonmez A; Ozgurtas T; Aydin A; Eyileten T; Ozcan O; Acikel C; Tasar M; Genctoy G; Erbil K; Vural A; Zoccali C
    Am J Kidney Dis; 2006 Jan; 47(1):42-50. PubMed ID: 16377384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Yamada S; Takeuchi M; Fukami K; Ueda S; Adachi H; Matsui T; Okuda S; Yamagishi S
    Metabolism; 2009 Nov; 58(11):1624-8. PubMed ID: 19604520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients.
    Ebinç FA; Erten Y; Ebinç H; Paşaoğlu H; Demirtaş C; Taçoy G; Mutluay R; Koç E; Derici U; Reis KA; Bali M; Arinsoy T; Sindel S
    Ren Fail; 2008; 30(4):401-6. PubMed ID: 18569913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study.
    Eiselt J; Rajdl D; Racek J; Vostrý M; Rulcová K; Wirth J
    Kidney Blood Press Res; 2014; 39(1):50-7. PubMed ID: 24923294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
    Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
    Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of advanced glycation end-products with glutathione status.
    Sahin E; Göçmen AY; Koçak H; Tuncer M; Gümüslü S
    Ann Clin Biochem; 2008 Jul; 45(Pt 4):369-74. PubMed ID: 18583621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal effects of low-dose ACE inhibition on endothelial function in Type 1 diabetic patients.
    Yazici D; Yavuz DG; Unsalan S; Toprak A; Yüksel M; Deyneli O; Aydin H; Tezcan H; Rollas S; Akalin S
    J Endocrinol Invest; 2007 Oct; 30(9):726-33. PubMed ID: 17993763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
    van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
    Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Suzuki T; Ueda Y; Yamada S; Shoji H; Takeuchi M; Ueda S; Matsui T; Adachi H; Okuda S; Yamagishi S
    Pharmacol Res; 2009 Dec; 60(6):515-8. PubMed ID: 19450686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids.
    Ueda Y; Miyata T; Goffin E; Yoshino A; Inagi R; Ishibashi Y; Izuhara Y; Saito A; Kurokawa K; Van Ypersele De Strihou C
    Kidney Int; 2000 Dec; 58(6):2518-24. PubMed ID: 11115086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum asymmetric dimethylarginine and endothelial function after renal transplantation.
    Zhang W; Zhou C; Xie J; Chen B; Chang L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 34(4):289-94. PubMed ID: 19411743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of inflammation and protein-energy wasting with endothelial dysfunction in peritoneal dialysis patients.
    Choi HY; Lee JE; Han SH; Yoo TH; Kim BS; Park HC; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
    Nephrol Dial Transplant; 2010 Apr; 25(4):1266-71. PubMed ID: 19926717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
    Göçmen AY; Sahin E; Koçak H; Tuncer M; Gümüşlü S
    Clin Biochem; 2008 Jul; 41(10-11):836-40. PubMed ID: 18457672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis.
    Jiang J; Chen P; Chen J; Yu X; Xie D; Mei C; Xiong F; Shi W; Zhou W; Liu X; Sun S; Zhang P; Yang X; Zhang Y; Zhang Y; Liang X; Zhang Z; Lin Q; Yu Y; Miyata T; Tian J; Liang M; Luo W; Xu X; Hou F
    Atherosclerosis; 2012 Sep; 224(1):187-94. PubMed ID: 22857897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms for the formation of glycoxidation products in end-stage renal disease.
    Weiss MF; Erhard P; Kader-Attia FA; Wu YC; Deoreo PB; Araki A; Glomb MA; Monnier VM
    Kidney Int; 2000 Jun; 57(6):2571-85. PubMed ID: 10844627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.